Condition: Esophageal Squamous Cell Carcinoma (ESCC) · Sponsor: Sun Yat-sen University
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal squamous cell carcinoma (ESCC). The primary research objectives are to increase the R0 resection rate in such patients, thereby reducing the recurrence rate and improving overall survival (OS), as well as avoiding adverse reactions associated with radiotherapy.
This description comes directly from the study's public registry record.
Hong Yang, MD, PhD · 86-13560405144 · yanghong@sysucc.org.cn
Chief physician · 86-13560405144
Always discuss trial participation with your own doctor first.
| No. 651 Dongfeng East Road, Guangzhou | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07638436